954239-34-0 Usage
Uses
Used in Organic Synthesis:
1-BOC-6-IODO-2,3-DIHYDRO-INDOLE is used as a building block for the synthesis of complex natural products and other organic compounds. Its unique structure and reactivity make it a valuable component in the creation of novel chemical entities with diverse biological activities.
Used in Pharmaceutical Research:
1-BOC-6-IODO-2,3-DIHYDRO-INDOLE is used as a key intermediate in drug discovery and development. Its protected amine functionality and iodo group allow for further chemical modifications and the synthesis of new drug candidates with potential therapeutic applications.
Used in Medicinal Chemistry:
1-BOC-6-IODO-2,3-DIHYDRO-INDOLE is used as a starting material for the design and synthesis of new pharmaceutical agents. Its unique structural features and reactivity enable the development of innovative drug molecules with improved potency, selectivity, and pharmacokinetic properties.
Used in Chemical Biology:
1-BOC-6-IODO-2,3-DIHYDRO-INDOLE is used as a probe or tool compound in chemical biology research. Its ability to modulate biological processes and interact with target proteins makes it a valuable asset in the study of disease mechanisms and the identification of new therapeutic targets.
Check Digit Verification of cas no
The CAS Registry Mumber 954239-34-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,4,2,3 and 9 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 954239-34:
(8*9)+(7*5)+(6*4)+(5*2)+(4*3)+(3*9)+(2*3)+(1*4)=190
190 % 10 = 0
So 954239-34-0 is a valid CAS Registry Number.
954239-34-0Relevant academic research and scientific papers
Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors
Varnes, Jeffrey G.,Wacker, Dean A.,Jacobson, Irina C.,Quan, Mimi L.,Ellis, Christopher D.,Rossi, Karen A.,He, Ming Y.,Luettgen, Joseph M.,Knabb, Robert M.,Bai, Steven,He, Kan,Lam, Patrick Y.S.,Wexler, Ruth R.
, p. 6481 - 6488 (2008/03/18)
A new series of pyrazole-based factor Xa inhibitors have been identified as part of our ongoing efforts to optimize previously reported clinical candidate razaxaban. Concern over the possible formation of primary aniline metabolites via amide hydrolysis led to the replacement of the primary amide linker between the pyrazole and phenyl moieties with secondary amides. This was accomplished by replacing the aniline with a variety of heterobicycles, of which indolines were the most potent. The indoline series demonstrated subnanomolar factor Xa binding Kis, modest to high selectivity versus other serine proteases, and good in vitro clotting activity. A small number of indoline fXa inhibitors were profiled in a dog pharmacokinetic model, one of which demonstrated pharmacokinetic parameters similar to that of clinical candidate razaxaban.
